Skip to main content

Table 1 Association of CDK5 expression and Ki-67 LI with clinicopathological features

From: Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study

Parameters Total (n) Expression of CDK5 n (%) Z P Ki-67 relevant expression (2−ΔCq) t P
Negative Positive Mean ± SD
Tissue
 Normal tissue 16 14 (87.5 %) 2 (12.5 %) −3.400 0.001 0.6062 ± 0.9518 −12.464 <0.001
 Glioma 152 65 (42.8 %) 87 (57.2 %) 11.4053 ± 10.2714
Gender
 Female 49 23 (46.9 %) 23 (53.1 %) −0.014 0.989 10.6449 ± 10.4964 0.216 0.829
 Male 119 56 (47.1 %) 63 (52.9 %) 10.2664 ± 10.2259
Age (median)
 ≤41.5 84 34 (40.5 %) 40 (59.5 %) −1.695 0.09 11.5940 ± 10.6489 1.542 0.125
 >41.5 84 45 (53.6 %) 39 (46.4 %) 9.1595 ± 9.8001
Grading1
 I–II 67 39 (58.2 %) 28 (41.8 %) −3.406 0.001 2.0373 ± 1.8660 −18.988 <0.001
 III–IV 85 26 (30.6 %) 59 (69.4 %) 18.7864 ± 7.85763
Grading2
 I 23 15 (65.2 %) 8 (34.8 %) 15.482a 0.001 2.0000 ± 2.5045 104.022b <0.001
 II 44 24 (54.5 %) 20 (45.5 %) 2.0568 ± 1.4609
 III 56 21 (37.5 %) 35 (62.5 %) 17.4571 ± 7.3644
 IV 29 5 (17.2 %) 24 (82.8 %) 21.3621 ± 8.2639
CDK5
 Low 79      6.5380 ± 8.4147 −4.928 <0.001
 High 89    13.7843 ± 10.6130
Ki-67 (median)
 Low 84 54 (64.3 %) 30 (35.7 %) −4.469 <0.0001    
 High 84 25 (29.8 %) 59 (70.2 %)    
  1. aKruskal-Wallis H test was performed
  2. bOne-way analysis of variance (ANOVA) test was used